Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Estimated migraine acute-therapy savings, from MMD reduction achieved with preventive treatment
Headache Posters (7:00 AM-5:00 PM)

Migraine therapies are distinguished as ‘acute’ – used during an attack to alleviate symptoms/disability – or ‘preventive’ – used to reduce attack frequency/severity. Frequency is commonly measured in MMDs, days when patients might use a prescription acute therapy, such as a triptans. Preventive therapies that reduce MMDs therefore may yield reduced acute-therapy use, and associated cost savings. The magnitude of such savings is uncertain, however, due to the range of costs/dose of triptans and of patients’ MMDs and rate/timing of response to preventive treatment.